Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Man, double blind, placebo controlled Phase 1 clinical study evaluating the safety, tolerability and pharmacokinetics of single ascending doses of BX2000 in healthy volunteers

Next Previous
Trial Profile

A First-in-Man, double blind, placebo controlled Phase 1 clinical study evaluating the safety, tolerability and pharmacokinetics of single ascending doses of BX2000 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BX 2000 (Primary)
  • Indications Anaesthesia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Baudax Bio

Most Recent Events

  • 23 Feb 2023 According to Baudax Bio media release, the Company expects to complete enrollment of the remaining cohorts in the study by end of 2023
  • 08 Nov 2022 According to Baudax Bio media release, first and second cohorts dosed and enrollment of the third cohort underway, the Company expects to complete enrollment of the remaining cohorts in the study in by mid-2023.
  • 01 Jun 2022 According to Baudax Bio media release, the first cohort has been dosed in this study; the company look forward to assessing the safety, PK and profile as the study completes enrollment in late 2022 or early 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top